Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola
The 2014-2016 Ebola outbreak in West Africa was the largest in history leading to 28,639 cases, of which 40% were fatal. Better treatments and effective vaccines against Ebola virus are needed to prevent future recurrence. Multiple, novel, treatment options were assessed during the outbreak, includi...
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Conference item |
| Foilsithe / Cruthaithe: |
Elsevier
2017
|
| _version_ | 1826268456743337984 |
|---|---|
| author | Tan, T Rijal, P Townsend, A Hyde, S Gill, D |
| author_facet | Tan, T Rijal, P Townsend, A Hyde, S Gill, D |
| author_sort | Tan, T |
| collection | OXFORD |
| description | The 2014-2016 Ebola outbreak in West Africa was the largest in history leading to 28,639 cases, of which 40% were fatal. Better treatments and effective vaccines against Ebola virus are needed to prevent future recurrence. Multiple, novel, treatment options were assessed during the outbreak, including ZMapp™ monoclonal antibody therapy, which showed promising results in some patients. However, widespread adoption of this approach is hindered by high costs of monoclonal antibody manufacturing and the relatively short half-life of antibody in the blood circulation. To circumvent such limitations, we propose to utilise recombinant adeno-associated virus (rAAV) delivered to the muscle to express the therapeutic monoclonal antibodies. |
| first_indexed | 2024-03-06T21:09:56Z |
| format | Conference item |
| id | oxford-uuid:3dcbec8c-3e81-46c2-857b-90ecee9b574b |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:09:56Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:3dcbec8c-3e81-46c2-857b-90ecee9b574b2022-03-26T14:21:37ZDevelopment of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebolaConference itemhttp://purl.org/coar/resource_type/c_5794uuid:3dcbec8c-3e81-46c2-857b-90ecee9b574bSymplectic Elements at OxfordElsevier2017Tan, TRijal, PTownsend, AHyde, SGill, DThe 2014-2016 Ebola outbreak in West Africa was the largest in history leading to 28,639 cases, of which 40% were fatal. Better treatments and effective vaccines against Ebola virus are needed to prevent future recurrence. Multiple, novel, treatment options were assessed during the outbreak, including ZMapp™ monoclonal antibody therapy, which showed promising results in some patients. However, widespread adoption of this approach is hindered by high costs of monoclonal antibody manufacturing and the relatively short half-life of antibody in the blood circulation. To circumvent such limitations, we propose to utilise recombinant adeno-associated virus (rAAV) delivered to the muscle to express the therapeutic monoclonal antibodies. |
| spellingShingle | Tan, T Rijal, P Townsend, A Hyde, S Gill, D Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title | Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title_full | Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title_fullStr | Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title_full_unstemmed | Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title_short | Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola |
| title_sort | development of recombinant adeno associated viral vector raav for passive immunisation against ebola |
| work_keys_str_mv | AT tant developmentofrecombinantadenoassociatedviralvectorraavforpassiveimmunisationagainstebola AT rijalp developmentofrecombinantadenoassociatedviralvectorraavforpassiveimmunisationagainstebola AT townsenda developmentofrecombinantadenoassociatedviralvectorraavforpassiveimmunisationagainstebola AT hydes developmentofrecombinantadenoassociatedviralvectorraavforpassiveimmunisationagainstebola AT gilld developmentofrecombinantadenoassociatedviralvectorraavforpassiveimmunisationagainstebola |